Kim Margolin, M.D.
- Medical Oncology
- Germ Cell Cancer
Dr. Margolin earned her undergraduate degree summa cum laude from University of California, Los Angeles, graduating Phi Beta Kappa, then went on to receive her medical degree from Stanford University School of Medicine. After internal medicine residency at Yale-New Haven Hospital in New Haven, CT, Dr. Margolin began her fellowship in hematology/oncology at the University of California, San Diego School of Medicine and completed the fellowship in medical oncology and hematology and bone marrow transplantation at City of Hope. She remained on the City of Hope faculty in both departments for 25 years prior to her recruitment to Seattle.
Triple board-certified in internal medicine with subspecialties in medical oncology and hematology, Dr. Margolin is a fellow of the American College of Physicians. She is on the editorial board of the Journal of Immunotherapy and is section editor in melanoma for the journal Cancer. Dr. Margolin has chaired numerous institutional committees, professional societies and advisory boards. She has been the Chair of the Cancer Education Committee and a member of the Nominating Committee of ASCO and previously served as a member of the Oncologic Drug Advisory Committee (ODAC) of the FDA.
Dr. Margolin is also an active member of several foundation and federal grant review committees, including the Melanoma Research Alliance, Department of Defense and Melanoma Research Foundation. Among her 180 peer-reviewed articles, 60 invited reviews or editorials, and 16 book chapters, her most recent work has been in the area of melanoma metastatic to the brain and immunotherapy strategies for melanoma and other skin cancers. Dr. Margolin is frequently invited to present her work at national and international conferences and symposia.
- 2016 to present, Clinical Professor, Department of Medical Oncology & Therapeutics, City of Hope, Duarte, CA
- 2014, Professor, Stanford University Division of Medical Oncology, co-director Pigmented Lesions and Melanoma Program, Stanford, CA
- 2011 - 2014, Associate Director for the HEMEONC Fellowship, University of Washington, Seattle, Washington
- 2008 - 2014, Professor, Division of Oncology, University of Washington, Seattle, Washington
- 2004 - 2006, Acting Associate Director for Clinical Research, City of Hope Comprehensive Cancer Center, Duarte, CA
- 1995 - 2008, Associate Director for Clinical Research, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
- 1985 - 2008, Staff Physician, Departments of Medical Oncology & Therapeutics Research and Hematology & Hematopoietic Cell Transplant, City of Hope, Duarte, CA
- Skin Cancer/Melanoma
- 1979, Stanford University School of Medicine, Stanford, California (Medical Scientist Training Program, laboratory of Dr. David Clayton), M.S.
- 1974. Phi Beta Kappa, University of California at Los Angeles (UCLA), B.S.in Biochemistry with departmental honors and summa cum laude.
- 2006, American Board of Internal Medicine, subspecialty exam in Medical Oncology, recertification
- 1987, American Board of Internal Medicine, subspecialty exam in Hematology
- 1986, American Board of Internal Medicine, subspecialty exam in Medical Oncology
- 1982, American Board of Internal Medicine
- 1980, National Board of Medical Examiners
September 06, 2018
July 26, 2018
March 17, 2017
July 12, 2016
Nieto Y, Tu S-M, Jones RB, Bassett MS, Tannir N, Gulbis AM, Kingham A, Ledesma C, Margolin KA, Holmberg L, Champlin R, Pagliaro L Bevacizumab/High-Dose Chemotherapy with Autologous Stem-Cell Transplant for Refractory Germ Cell Tumors (submitted)
Grossmann KF and Margolin K Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic Advances in Medical Oncology 2015
Hurwitz A, Lee SM, Knox S, Kohrt H, Verdeil G, Romano E, Margolin K, Urba WJ, Speiser DE. 29th Annual Meeting of the Society of Immunotherapy of Cancer (JITC 3, 2015—online)
Ribas et al. Pembrolizumab in ipilimumab-refractory melanoma (Lancet Oncology, in press)
National Comprehensive Cancer Network Clinical Practice Guidelines for the Follow-Up Management of Testicular-Cancer Patients: A Multidisciplinary Consensus-Based ApproachClair J. Beard, M.D;1 Shilpa Gupta, M.D;2 Robert J. Motzer, M.D.;3 Elizabeth K. O’Donnell, M.D.;4 Elizabeth R. Plimack, M.D., M.S.;5 Kim A. Margolin, M.D.;6 Charles J. Ryan, M.D.;7 Joel Sheinfeld, M.D.;8 and Darren R. Feldman, M.D.9 (JNCCN, in press)
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA.Cancer. 2015 Feb 1;121(3):432-40. doi: 10.1002/cncr.29055. Epub 2014 Sep 23.PMID: 25250858 [PubMed - in process]
Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. Sundarakumar DK, Marshall DA, Keene CD, Rockhill JK, Margolin KA, Kim LJ.J Neurointerv Surg. 2014 Sep 25. pii: neurintsurg-2014-011362. doi: 10.1136/neurintsurg-2014-011362.rep. [Epub ahead of print] PMID: 25261441 [PubMed - as supplied by publisher]
David H. Lawson1, Sandra J. Lee2, Fengmin Zhao2, Ahmad A. Tarhini3, Theresa L. Whiteside3, Lisa H. Butterfield3, Kim A. Margolin4, Marc S. Ernstoff5, Michael B. Atkins6, Gary I. Cohen7, John M. Kirkwood3A Randomized Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF vs. Peptide Vaccination vs. GM-CSF Plus Peptide Vaccination vs. Placebo in Patients without Evidence of Disease after Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: An Intergroup Trial led by the Eastern Cooperative Oncology Group (E4697) JCO 2015 in press
Flaherty KT, Manola J, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. ECOG E2804: A Randomized Phase II Study of VEGF, RAF Kinase and mTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma (Journal of Clinical Oncology, in press)
Kim A Margolin, MD,a Ahmad Tarhini, MD, PhD,b Sumati Rao, PhD,c Monica Katyal, JD, MPH,d I-Fen Chang, PharmD,c Douglas B. Johnson, MD,e Sekwon Jang, MD,f Joseph I. Clark, MD,g and David McDermott, MDh Effectiveness and safety of ipilimumab therapy in melanoma: evidence from a US multisite observational chart review. Journal of Supportive and Community Oncology (2015) 13, 131-138
Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY; Response Assessment in Neuro-Oncology (RANO) group Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep;14(10):e396-406. doi:
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014 Dec 1. pii: JCO.2014.59.0703. [Epub ahead of print]
The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. Clin Cancer Res. 2014 Nov 25. pii: clincanres.1520.2014. [Epub ahead of print]
Schadendorf, D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T, Berman DM, Wolchok JD. Pooled Analysis of Long-term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015 Feb 9 epub Patient accrual, extensive assistance with manuscript writing